Seven years after the approval of the first chimeric antigen receptor T-cell therapies, the Center for Biologics Evaluation and Research is starting to see a “branching out” within cell-based gene therapies into “much more complicated constructs,” CBER Director Peter Marks said during a 6 May webinar sponsored by the Friends of Cancer Research and Parker Institute for Cancer Immunotherapy.
Key Takeaways
-
Marks expects an “expedited evolution” of cell and gene therapy development, especially with products relying on CRISPR.
“We’re in a place now where there’s a subtle change,” Marks observed.
